Search results
Exelixis (EXEL) Outperforms Industry in 1H22: What Lies Ahead?
Zacks via Yahoo Finance· 2 years agoExelixis EXEL has had a good run so far this year. In fact, it is one of the few biotech stocks that...
Exelixis (EXEL) Reports Positive Cabometyx Combo Study Results
Zacks via Yahoo Finance· 2 years agoExelixis EXEL has announced detailed results from the ongoing phase III study, COSMIC-313. The...
Exelixis (EXEL) Collaborates With Ryvu for Cancer Therapies
Zacks via Yahoo Finance· 2 years agoExelixis EXEL has announced that it entered into an exclusive license agreement with Ryvu...
BeiGene's Tislelizumab Shows Non-Inferiority In Overall Survival, Safety Vs Standard Treatment In...
Benzinga via Yahoo Finance· 2 years agoBeiGene Limited (NASDAQ: BGNE) shared updates from its solid tumor development program for...
SpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch
Benzinga via Yahoo Finance· 2 years agoHC Wainwright points out that investors are enthusiastic about SpringWorks Therapeutics Inc (NASDAQ:...
Is This Chinese Pharmaceutical Stock Worth the Risk?
Motley Fool· 2 years agoBeiGene (NASDAQ: BGNE), is a Chinese biopharmaceutical company with offices in Cambridge, Massachusetts; Basel, Switzerland; and Beijing. It focuses on...
Exelixis (EXEL) Announces Preliminary Q4 and 2022 Results
Zacks via Yahoo Finance· 1 year agoExelixis EXEL announced preliminary financial results for the fourth quarter and full year 2022 and...
Bristol Myers (BMY) Gets EC Nod for Abecma's Label Expansion
Zacks via Yahoo Finance· 3 months agoBristol Myers (BMY) wins European Commission's approval for the label expansion of its CAR T cell...
Exelixis (EXEL) Reports Data from CONTACT-01, QUARTZ-101 Study
Zacks via Yahoo Finance· 1 year agoExelixis (EXEL) announces that the phase III study, CONTACT-01, did not meet its primary endpoint....